Cocrystal Pharma Inc. (COCP)

3.12
NASDAQ : Health Technology
Prev Close 3.43
Day Low/High 2.92 / 3.27
52 Wk Low/High 1.51 / 7.44
Avg Volume 45.60K
Exchange NASDAQ
Shares Outstanding 29.92M
Market Cap 105.93M
P/E Ratio 85.75
Div & Yield N.A. (N.A)

Latest News

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Cocrystal Pharma, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Cocrystal Pharma, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Cocrystal Pharma, Inc.

COCP LOSS ALERT: Rosen Law Firm Reminds Cocrystal Pharma, Inc. Investors Of Important Deadline In First Filed Case; Important Deadline - COCP

COCP LOSS ALERT: Rosen Law Firm Reminds Cocrystal Pharma, Inc. Investors Of Important Deadline In First Filed Case; Important Deadline - COCP

NEW YORK, Nov. 2, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cocrystal Pharma, Inc.

Deadline Alert: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Cocrystal Pharma, Inc.

Deadline Alert: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Cocrystal Pharma, Inc.

Law Offices of Howard G. Smith reminds investors of the November 19, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Cocrystal Pharma, Inc.

Lifshitz & Miller LLP Announces Investigation Of Adient PLC, Applied Optoelectronics, Inc., Cocrystal Pharma, Inc., Microchip Technology Incorporated, MGT Capital Investments, Inc., TG Therapeutics, Inc. And USA Technologies, Inc.

Lifshitz & Miller LLP Announces Investigation Of Adient PLC, Applied Optoelectronics, Inc., Cocrystal Pharma, Inc., Microchip Technology Incorporated, MGT Capital Investments, Inc., TG Therapeutics, Inc. And USA Technologies, Inc.

NEW YORK, Oct. 30, 2018 /PRNewswire/ --  Adient PLC (ADNT) Lifshitz & Miller announces investigation into possible securities laws violations in connection with ADNT's CEO stepping down and decreased profit forecast for the year.

Scott Scott Attorneys At Law LLP Reminds Investors Of Securities Class Action Against Cocrystal Pharma, Inc., Formerly Known As BioZone Pharmaceuticals, Inc. (COCP) And November 19 Plaintiff Deadline

Scott Scott Attorneys At Law LLP Reminds Investors Of Securities Class Action Against Cocrystal Pharma, Inc., Formerly Known As BioZone Pharmaceuticals, Inc. (COCP) And November 19 Plaintiff Deadline

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Cocrystal Pharma, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Cocrystal Pharma, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Cocrystal Pharma, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Cocrystal Pharma, Inc.

Glancy Prongay & Murray LLP Announces The Filing Of A Securities Class Action On Behalf Of Cocrystal Pharma, Inc. Investors (COCP)

Glancy Prongay & Murray LLP Announces The Filing Of A Securities Class Action On Behalf Of Cocrystal Pharma, Inc. Investors (COCP)

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired Cocrystal Pharma, Inc.

COCP NOTICE: Rosen Law Firm Files First Securities Class Action Lawsuit Against Cocrystal Pharma, Inc. - COCP (formerly Known As BioZone Pharmaceuticals, Inc. - BZNE)

COCP NOTICE: Rosen Law Firm Files First Securities Class Action Lawsuit Against Cocrystal Pharma, Inc. - COCP (formerly Known As BioZone Pharmaceuticals, Inc. - BZNE)

NEW YORK, Oct. 6, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Cocrystal Pharma, Inc.

COCRYSTAL LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Cocrystal Pharma, Inc. To Contact The Firm

COCRYSTAL LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Cocrystal Pharma, Inc. To Contact The Firm

NEW YORK, Oct. 2, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Cocrystal Pharma, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Cocrystal Pharma, Inc. F/k/a BioZone - COCP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Cocrystal Pharma, Inc. F/k/a BioZone - COCP

NEW YORK, Oct. 2, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cocrystal Pharma, Inc.

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Cocrystal Pharma, Inc. (formerly BioZone Pharmaceuticals, Inc.) Investors

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Cocrystal Pharma, Inc. (formerly BioZone Pharmaceuticals, Inc.) Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Cocrystal Pharma, Inc.

COCP NOTICE: Rosen Law Firm Reminds Investors Of Cocrystal Pharma, Inc. Of Upcoming Deadline In Class Action - COCP (formerly Known As BioZone Pharmaceuticals, Inc. - BZNE)

COCP NOTICE: Rosen Law Firm Reminds Investors Of Cocrystal Pharma, Inc. Of Upcoming Deadline In Class Action - COCP (formerly Known As BioZone Pharmaceuticals, Inc. - BZNE)

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cocrystal Pharma, Inc.

Scott Scott Attorneys At Law LLP Alerts Investors To The Filing Of Securities Class Action Against Cocrystal Pharma, Inc., Formerly Known As BioZone Pharmaceuticals, Inc. (COCP)

Scott Scott Attorneys At Law LLP Alerts Investors To The Filing Of Securities Class Action Against Cocrystal Pharma, Inc., Formerly Known As BioZone Pharmaceuticals, Inc. (COCP)

NEW YORK, Sept. 25, 2018 /PRNewswire/ --  Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against Cocrystal Pharma, Inc.

COCRYSTAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Cocrystal Pharma, Inc. To Contact The Firm

COCRYSTAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Cocrystal Pharma, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cocrystal Pharma, Inc.

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Cocrystal Pharma, Inc. F/k/a/ BioZone Pharmaceuticals, Inc. (COCP) And Lead Plaintiff Deadline - November 19, 2018

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Cocrystal Pharma, Inc. F/k/a/ BioZone Pharmaceuticals, Inc. (COCP) And Lead Plaintiff Deadline - November 19, 2018

NEW YORK, Sept. 21, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cocrystal Pharma, Inc.

COCRYSTAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Cocrystal Pharma, Inc. To Contact The Firm

COCRYSTAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Cocrystal Pharma, Inc. To Contact The Firm

NEW YORK, Sept. 21, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cocrystal Pharma, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Cocrystal Pharma, Inc., Formerly Known As BioZone Pharmaceuticals, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Cocrystal Pharma, Inc., Formerly Known As BioZone Pharmaceuticals, Inc.

Federman & Sherwood announces that on September 20, 2018, a class action lawsuit was filed in the United States District Court for the District of New Jersey against Cocrystal Pharma, Inc.

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Cocrystal Pharma, Inc. - COCP (formerly Known As BioZone Pharmaceuticals, Inc. - BZNE)

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Cocrystal Pharma, Inc. - COCP (formerly Known As BioZone Pharmaceuticals, Inc. - BZNE)

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Cocrystal Pharma, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Cocrystal Pharma, Inc. - COCP (formerly BioZone Pharmaceuticals, Inc. - BZNE)

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Cocrystal Pharma, Inc. - COCP (formerly BioZone Pharmaceuticals, Inc. - BZNE)

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Uplist To The Nasdaq Capital Market

Cocrystal Pharma Announces Uplist To The Nasdaq Capital Market

- Company's common stock to commence trading on Nasdaq on March 12, 2018 -

IDI Management Fires Back Against Blog Post

Executives say investor Philip Frost supports them and the company.

Jim Cramer Thinks This Big Biotech Stock Can 'Power Higher'

Jim Cramer Thinks This Big Biotech Stock Can 'Power Higher'

Cramer has been a big believer in Opko Health, which has been on a run since Pfizer put down nearly $300 million for one of its drugs. More upside possible?